Colgan Erin
Known title: Chief Financial OfficerCIK: 0001843563
Associated companies
Transaction History
| FTH | ▼ Sell | Tax Withholding | 3,627 | $3K | 2/15/2024 | View on chart |
| FTH | ▼ Sell | Tax Withholding | 10,943 | $16K | 2/15/2023 | View on chart |
| FTH | ▲ Buy | Grant | 21,300 | $0 | 2/15/2023 | View on chart |
| FTH | ▲ Buy | Grant | 30,046 | $0 | 2/15/2023 | View on chart |
| FTH | ▲ Buy | Grant | 21,000 | $0 | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH)
William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.